MongoliaTuberculosis profile
Population  2015 3 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.64 (0.42–0.91) 22 (14–31)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.06 (0.01–0.17)
Incidence  (includes HIV+TB) 13 (6.5–21) 428 (220–703)
Incidence (HIV+TB only) 0.01 (<0.01–0.013) 0.34 (0.26–0.44)
Incidence (MDR/RR-TB)** 0.63 (0.37–0.89) 21 (13–30)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.44 (0.2–0.68) 5.1 (1.9–8.2) 5.5 (2.1–8.9)
Males 0.41 (0.24–0.58) 6.7 (4.2–9.3) 7.1 (4.5–9.8)
Total 0.85 (0.54–1.2) 12 (8.1–16) 13 (6.5–21)
TB case notifications, 2015  
Total cases notified 4 935
Total new and relapse 4 685
          - % tested with rapid diagnostics at time of diagnosis 13%
          - % with known HIV status 80%
          - % pulmonary 57%
          - % bacteriologically confirmed among pulmonary 78%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 37% (23–72)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.06 (0.03–0.11)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 6 <1%
          - on antiretroviral therapy 6 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  240
(210–280)
Estimated % of TB cases with MDR/RR-TB 2.2% (1.1–3.3) 33% (29–38)  
% notified tested for rifampicin resistance 23% 56% 1 366
MDR/RR-TB cases tested for resistance to second-line drugs   23
Laboratory-confirmed cases MDR/RR-TB: 243, XDR-TB: 4
Patients started on treatment **** MDR/RR-TB: 273, XDR-TB: 5
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 86% 4 483
Previously treated cases, excluding relapse, registered in 2014 74% 288
HIV-positive TB cases, all types, registered in 2014 75% 8
MDR/RR-TB cases started on second-line treatment in 2013 56% 181
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 0%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
17% (16–19)
TB financing, 2016  
National TB budget (US$ millions) 4
Funding source: 63% domestic, 37% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data